LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

Home・Akciju saraksts・Incyte Corp

Incyte Corp

Slēgts

SektorsVeselības aprūpe

98.39 -0.67

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

96.99

Max

99.05

Galvenie mērījumi
By Trading Economics
Ienākumi	4.1M 303M
Pārdošana	-234M 1.3B
P/E Sektora vidējais	14.17 51.415
EPS	1.81
Peļņas marža	23.834
Darbinieki	2,844
EBITDA	-47M 367M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+10.09% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 28. jūl.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	993M 20B
Iepriekšējā atvēršanas cena	99.06
Iepriekšējā slēgšanas cena	98.39

Ziņu noskaņojums

By Acuity

35%

65%

111 / 346 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

59.52 / 62.66 Atbalsts un pretestība

Incyte Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 13. maijs 22:54 UTC

Peļņas

Xero Lifts Annual Earnings 18%, Flags More Growth Ahead

2026. g. 13. maijs 23:51 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 13. maijs 23:51 UTC

Tirgus saruna

Australian Consumer Spending Is Holding Up; RBA Watching -- Market Talk

2026. g. 13. maijs 23:45 UTC

Tirgus saruna

Nikkei May Rise After Overnight U.S. Tech Gains -- Market Talk

2026. g. 13. maijs 23:45 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 13. maijs 23:17 UTC

Peļņas

Samsung Fire & Marine Insurance 1Q Net Profit Beat FactSet-Compiled Consensus

2026. g. 13. maijs 23:16 UTC

Peļņas

Samsung Fire & Marine Insurance 1Q Net KRW635.22B Vs. Net KRW609.03B >000810.SE

2026. g. 13. maijs 23:15 UTC

Peļņas

Samsung Fire & Marine Insurance 1Q Oper Pft KRW861.13B Vs. Pft KRW792.36B >000810.SE

2026. g. 13. maijs 23:14 UTC

Peļņas

Samsung Fire & Marine Insurance 1Q Rev KRW6.676T Vs. KRW6.106T >000810.SE

2026. g. 13. maijs 23:02 UTC

Tirgus saruna

Peļņas

Cisco Product Demand Climbing Even Without Hyperscalers -- Market Talk

2026. g. 13. maijs 22:59 UTC

Tirgus saruna

Peļņas

Cisco Boosted by Tech Infrastructure Upgrade Cycle -- Market Talk

2026. g. 13. maijs 22:24 UTC

Peļņas

Xero FY U.S. Organic Revenue Growth 30%>XRO.AU

2026. g. 13. maijs 22:23 UTC

Peļņas

Xero FY International Organic Revenue Growth 25%>XRO.AU

2026. g. 13. maijs 22:23 UTC

Peļņas

Xero FY International Revenue Growth 47%>XRO.AU

2026. g. 13. maijs 22:22 UTC

Peļņas

Xero FY Australia, New Zealand Revenue Up 18% on Year >XRO.AU

2026. g. 13. maijs 22:19 UTC

Peļņas

Xero FY Australia, New Zealand Revenue Up 17% in Constant Currency>XRO.AU

2026. g. 13. maijs 22:19 UTC

Peļņas

Xero FY Net Customer Additions 506,000 Vs. 254,000>XRO.AU

2026. g. 13. maijs 22:18 UTC

Peļņas

Xero FY Rule of 40: 48.5% Vs. 44.3%>XRO.AU

2026. g. 13. maijs 22:16 UTC

Peļņas

Xero: Ebitda Guidance Includes NZD55M of Incremental U.S. Brand Spend>XRO.AU

2026. g. 13. maijs 22:15 UTC

Peļņas

Xero Expects FY27 Adjusted Ebitda of NZD860M-NZD920M>XRO.AU

2026. g. 13. maijs 22:15 UTC

Peļņas

Xero Expects FY27 Operating Revenue of NZD3.62B-NZD3.73B>XRO.AU

2026. g. 13. maijs 22:13 UTC

Peļņas

Xero FY Operating Expenses 70.5% of Operating Revenue Vs. 71.8%>XRO.AU

2026. g. 13. maijs 22:12 UTC

Peļņas

Xero FY Free Cash Flow NZD554.0M Vs. NZD506.7M>XRO.AU

2026. g. 13. maijs 22:11 UTC

Peļņas

Xero FY Adjusted Ebitda NZD757.4M Vs. NZD641.8M>XRO.AU

2026. g. 13. maijs 22:11 UTC

Peļņas

Xero FY Ebitda NZD789.5M Vs. NZD638.5M>XRO.AU

2026. g. 13. maijs 22:10 UTC

Peļņas

Xero Did Not Declare a Dividend>XRO.AU

2026. g. 13. maijs 22:10 UTC

Peļņas

Xero FY Rev NZD2.75B Vs. NZD2.10B >XRO.AU

2026. g. 13. maijs 22:09 UTC

Peļņas

Xero FY Net NZD167.4M Vs. Net NZD227.8M >XRO.AU

2026. g. 13. maijs 22:00 UTC

Peļņas

Cisco to Shed Jobs for All-In AI Push -- Update

2026. g. 13. maijs 21:11 UTC

Peļņas

Cisco Earnings and Revenue Beat Estimates on Strong AI Demand. Its Shares Surge. -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Incyte Corp Prognoze

Cenas mērķis

By TipRanks

10.09% augšup

Prognoze 12 mēnešiem

Vidējais 109.13 USD 10.09%

Augstākais 135 USD

Zemākais 75 USD

Pamatojoties uz 17 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Incyte Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

17 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 17 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Incyte Corp — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

59.52 / 62.66Atbalsts un pretestība

Bullish events outweigh bearish events.

All events are bearish.

Noskaņojums

By Acuity

111 / 346 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation